Advances in S100 protein family for gynecological malignancies.

IF 2.9 4区 医学 Q3 ENDOCRINOLOGY & METABOLISM Discover. Oncology Pub Date : 2025-03-09 DOI:10.1007/s12672-025-02028-x
Shenglong Wu, Junfen Xu
{"title":"Advances in S100 protein family for gynecological malignancies.","authors":"Shenglong Wu, Junfen Xu","doi":"10.1007/s12672-025-02028-x","DOIUrl":null,"url":null,"abstract":"<p><p>The S100 protein family comprises more than 20 structurally related members with diverse functions. These proteins regulate cellular responses by acting both as intracellular Ca<sup>2+</sup> binding receptors and extracellular factors. Gynecological malignancies, characterized by tumors in the female reproductive system, like ovarian cancer (OC), cervical cancer (CC), and endometrial cancer (EC), cause significant harm to women's health. Dysregulated expression of certain S100 proteins is implicated not only in benign diseases but also in gynecological malignancies. Emerging in vitro evidence indicates these proteins play a key role in the occurrence and progression of such malignancies. Abnormal expression of specific S100 proteins contributes to malignancy progression by promoting proliferation, invasion, migration, and drug resistance. Furthermore, abnormal levels of some S100 proteins in serum and tissues are associated with diagnosis and prognosis, making them potential biomarkers. This review provides an overview of recent findings on the involvement of the S100 protein family in gynecological malignancies and explores their regulatory mechanisms.</p>","PeriodicalId":11148,"journal":{"name":"Discover. Oncology","volume":"16 1","pages":"287"},"PeriodicalIF":2.9000,"publicationDate":"2025-03-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891126/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Discover. Oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12672-025-02028-x","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

The S100 protein family comprises more than 20 structurally related members with diverse functions. These proteins regulate cellular responses by acting both as intracellular Ca2+ binding receptors and extracellular factors. Gynecological malignancies, characterized by tumors in the female reproductive system, like ovarian cancer (OC), cervical cancer (CC), and endometrial cancer (EC), cause significant harm to women's health. Dysregulated expression of certain S100 proteins is implicated not only in benign diseases but also in gynecological malignancies. Emerging in vitro evidence indicates these proteins play a key role in the occurrence and progression of such malignancies. Abnormal expression of specific S100 proteins contributes to malignancy progression by promoting proliferation, invasion, migration, and drug resistance. Furthermore, abnormal levels of some S100 proteins in serum and tissues are associated with diagnosis and prognosis, making them potential biomarkers. This review provides an overview of recent findings on the involvement of the S100 protein family in gynecological malignancies and explores their regulatory mechanisms.

Abstract Image

Abstract Image

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
妇科恶性肿瘤S100蛋白家族研究进展。
S100蛋白家族包括20多个具有不同功能的结构相关成员。这些蛋白通过作为细胞内Ca2+结合受体和细胞外因子调节细胞反应。妇科恶性肿瘤以女性生殖系统肿瘤为特征,如卵巢癌(OC)、宫颈癌(CC)和子宫内膜癌(EC),对女性健康造成重大危害。某些S100蛋白的表达失调不仅与良性疾病有关,也与妇科恶性肿瘤有关。越来越多的体外证据表明,这些蛋白在这些恶性肿瘤的发生和发展中起着关键作用。特异性S100蛋白的异常表达通过促进增殖、侵袭、迁移和耐药来促进恶性肿瘤的进展。此外,血清和组织中一些S100蛋白的异常水平与诊断和预后相关,使其成为潜在的生物标志物。本文综述了S100蛋白家族参与妇科恶性肿瘤的最新发现,并探讨了其调控机制。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Discover. Oncology
Discover. Oncology Medicine-Endocrinology, Diabetes and Metabolism
CiteScore
2.40
自引率
9.10%
发文量
122
审稿时长
5 weeks
期刊最新文献
Functional roles and clinical potential of SOX1 in cancer as a biomarker and therapeutic target. Global scientific growth and thematic development of spatial transcriptomics in oncology research. Prognostic impact of c-MYC and EZH2 expression in small cell and non-small cell lung carcinoma: a single-center retrospective study. PHC2 as a novel predictive biomarker and therapeutic target for cisplatin resistance in lung adenocarcinoma. Mapping research trends in immune cell metabolic reprogramming in breast cancer: a parallel dual-database bibliometric study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1